Could wet AMD patients get fewer eye shots? new study tests early treatment breaks
NCT ID NCT04932980
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two drugs, aflibercept and brolucizumab, for wet age-related macular degeneration (AMD). Instead of the usual three monthly loading doses, it tests starting with longer intervals between injections right away. The goal is to see if this approach works just as well while reducing the number of injections needed over a year. 80 patients aged 50 and older with active wet AMD are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aflibercept (Eylea) and Brolucizumab (Beovu) injections
- What this could lead to
- If successful, this could mean fewer eye injections for wet AMD patients without losing vision, making treatment less burdensome.
- What could go wrong
- This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The longer intervals might not control the disease as well as the standard approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Berner Augenklinik
Bern, 3007, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could eye drops replace injections for a leading cause of blindness?
- Eye injection burden varies by disease, study finds
- New hope for wet AMD patients: a simple pill may drain stubborn eye fluid
- Gene therapy could end frequent eye injections for wet AMD
- Gene therapy for wet AMD: could this mean fewer eye injections?
- New eye drug shows promise in battle against blinding disease